New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
13:19 EDTGALTGalectin Therapeutics volatility up into results from fatty liver disease trial
Galectin Therapeutics April call option implied volatility is at 188, May is at 145, July is at 112; compared to its 26-week average of 98 according to Track Data, suggesting large near term price movement into reporting results from the first cohort of its Phase 1 clinical trial examining GR-MD-02 in fatty liver disease.
News For GALT From The Last 14 Days
Check below for free stories on GALT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
08:42 EDTGALTGalectin Therapeutics drops after posting Phase I GT-020 slides
Subscribe for More Information
July 28, 2014
12:59 EDTGALTGalectin Therapeutics volatility up into Cohort 2 Phase 1 clinical trial results
Subscribe for More Information
12:44 EDTGALTGalectin pays for misleading press releases, The Street's Feuerstein says
Subscribe for More Information
11:00 EDTGALTHigh option volume stocks:
Subscribe for More Information
July 25, 2014
08:55 EDTGALTGalectin Therapeutics to host conference call
Conference call to discuss the Cohort 2 Phase 1 clinical trial results will be held on July 29 at 8:30 am. Webcast Link
July 22, 2014
10:46 EDTGALTHigh option volume stocks: SBAC KS EDU PII GALT EJ AXL TSEM HLF BCOR
Subscribe for More Information
08:44 EDTGALTGalectin Therapeutics announces first patient dosed in GR-MD-02 Phase 1B trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use